Kristi Roybal
Family · Cheyenne, WYNPI 1790160679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $732, 3.9 times the $190 reported in 2021. Among family clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$235
- AstraZeneca$230
- AbbVie$184
- GSK$177
- Bayer$164
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$123
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $235 |
| AstraZeneca(2 entities) | 12 | $230 |
| AbbVie(2 entities) | 9 | $184 |
| GSK | 11 | $177 |
| Bayer | 9 | $164 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $123 |
| Boehringer Ingelheim | 7 | $113 |
| Lilly USA, LLC | 6 | $93 |
| Exact Sciences | 5 | $92 |
| Viiv Healthcare Company | 3 | $90 |
| Abbott | 4 | $76 |
| Amgen | 5 | $74 |
| Eisai Inc. | 3 | $69 |
| Lundbeck LLC | 3 | $62 |
| Novartis | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Johnson & Johnson | 2 | $40 |
| Globus Medical | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 4 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Cequr Corporation | 2 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Merck | 1 | $14 |
| Corium, LLC | 1 | $7 |
How this compares
$2,217 in reported general payments places this provider in the 90th percentile of 284 family providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $62,644 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $38,083 |
| FarxigaDapagliflozin Propanediol | 34 | $31,075 |
| XareltoRivaroxaban | 20 | $15,518 |
| JardianceEmpagliflozin | 14 | $9,372 |
| CreonLipase/Protease/Amylase | 13 | $9,321 |
| GemtesaVibegron | 14 | $8,908 |
| JanuviaSitagliptin Phosphate | 12 | $6,459 |
| Saxagliptin Hcl | 12 | $5,270 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $4,950 |
| Levothyroxine Sodium | 222 | $1,859 |
| Omeprazole | 112 | $1,642 |
| Rosuvastatin Calcium | 13 | $1,418 |
| Atorvastatin Calcium | 137 | $1,315 |
| Losartan Potassium | 125 | $1,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $235 | $62,64453 claims |
| GSKTrelegy Ellipta | $177 | $38,08324 claims |
| AstraZenecaFarxiga | $230 | $31,07534 claims |
| Johnson & JohnsonXarelto | $40 | $15,51820 claims |
| Boehringer IngelheimJardiance | $113 | $9,37214 claims |
| AbbVieCreon | $184 | $9,32113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $25 | $8,90814 claims |
| MerckJanuvia | $14 | $6,45912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 284 family providers in Wyoming.
Other family in Cheyenne
- Jill GiranyCheyenne$44K
- Kathryn HeimerCheyenne$5K
- Greta SkagenCheyenne$4K
- Jennifer DavisCheyenne$4K
- Anne BarnesCheyenne$4K
- Katherine BrockCheyenne$3K
- Lana SykesCheyenne$3K
- Sheriedan GrannanCheyenne$3K
- Shala SwarmCheyenne$2K
- Heather RobertsCheyenne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.